Literature DB >> 27993579

Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer?

Eric M Tretter1, Joshua J Ebel2, Kamal S Pohar3, Debra L Zynger4.   

Abstract

Gross prosector analysis of perivesicular adipose tumor invasion is the sole differentiator between pT3 substages, and gross evaluation is critical to lymph node identification. Gross prosector impact on pT3 subclassification and lymph node counts in cystectomy specimens resected for bladder cancer has not been previously analyzed. Both pT3 subclassification and total number of lymph nodes removed at radical cystectomy for bladder cancer are considered important components of the pathology report; however, both have controversial prognostic significance. Our objective was to assess the impact of the gross prosector on pT3 substaging and lymph node count. Pathology reports from 560 cystectomy cases performed for primary bladder cancer were reviewed. Educational interventions regarding cystectomy gross prosector documentation were conducted. Gross prosectors did not document the presence or absence of macroscopic perivesicular adipose invasion in 17% of cases. There was a decrease in the frequency of cases lacking documentation after educational intervention (33% to 5%, P<.01). Most pT3 cases lacking documentation were classified as pT3a (75%). The percentage of pT3 cases classified as pT3a decreased after intervention (68% to 35%, P<.01). Overcounting of lymph nodes by gross prosectors was more common than undercounting (22% versus 2%). Pathology residents and prosectors with lower caseloads had more uncounted lymph packets (P<.01). In conclusion, we demonstrated an impact of the gross prosector on pT3 substaging and lymph node counts within bladder cancer resection specimens. This novel variable may confound the relationship of these parameters upon oncologic outcomes and should be incorporated into quality assurance programs.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Grossing; Lymph node; Prosector; pT3

Mesh:

Year:  2016        PMID: 27993579     DOI: 10.1016/j.humpath.2016.12.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  1 in total

1.  Utilization of Pelvic Lymph Node Dissection for Patients With Low-Risk Prostate Cancer Treated With Robot-Assisted Radical Prostatectomy.

Authors:  Parth K Modi; Megan Bock; Sinae Kim; Eric A Singer; Rahul R Parikh
Journal:  Clin Genitourin Cancer       Date:  2017-05-10       Impact factor: 2.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.